References
- Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. Science. American Association for the Advancement of Science. 2014;346:1258096. Available from: https://pubmed.ncbi.nlm.nih.gov/25430774/
- Komor AC, Badran AH, Liu DR. CRISPR-based technologies for the manipulation of Eukaryotic genomes. Cell. Cell Press. 2017;168:20–36. Available from: https://pubmed.ncbi.nlm.nih.gov/27866654/
- Urnov FD, Rebar EJ, Holmes MC, et al. Genome editing with engineered zinc finger nucleases. Nat Rev Genet Nat Rev Genet. 2010;11:636–646. Available from: https://pubmed.ncbi.nlm.nih.gov/20717154/
- Bogdanove AJ, Voytas DF. TAL effectors: customizable proteins for DNA targeting. Science. American Association for the Advancement of Science. 2011;333:1843–1846. Available from: https://pubmed.ncbi.nlm.nih.gov/21960622/
- Rodgers K, Mcvey M. Error-prone repair of DNA double-strand breaks J Cell Physiol. Wiley-Liss Inc. 2016;231:15–24. Available from: /pmc/articles/PMC4586358/?report=abstract
- Molla KA, Yang Y. CRISPR/Cas-mediated base editing: technical considerations and practical applications. Trends Biotechnol. Elsevier Ltd. 2019;37:1121–1142.
- Anzalone AV, Randolph PB, Davis JR, et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature.. 2019;576:149–157. Available from: /pmc/articles/PMC6907074/?report=abstract
- Brouns SJJ, Jore MM, Lundgren M, et al. Small CRISPR RNAs guide antiviral defense in prokaryotes. Science. 2008;321:960–964. Available from: https://pubmed.ncbi.nlm.nih.gov/18703739/
- van der Oost J, Jore MM, Westra ER, et al. CRISPR-based adaptive and heritable immunity in prokaryotes.Trends Biochem Sci. Elsevier. 2009;34:401–407. Available from: https://research.wur.nl/en/publications/crispr-based-adaptive-and-heritable-immunity-in-prokaryotes
- Makarova KS, Wolf YI, Iranzo J, et al. Evolutionary classification of CRISPR–Cas systems: a burst of class 2 and derived variants Nat Rev Microbiol. Nature Research. 2020 [cited 2020 Jul 16];18:67–83. Available from: https://pubmed.ncbi.nlm.nih.gov/31857715/
- Gootenberg JS, Abudayyeh OO, Kellner MJ, et al. Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a and Csm6. Science.. 2018;360:439–444. Available from: https://pubmed.ncbi.nlm.nih.gov/29449508/
- Kiga K, Tan XE, Ibarra-Chávez R, et al. Development of CRISPR-Cas13a-based antimicrobials capable of sequence-specific killing of target bacteria. Nat Commun. 2020;11. Available from: https://pubmed.ncbi.nlm.nih.gov/32523110/
- Abbott TR, Dhamdhere G, Liu Y, et al. Development of CRISPR as an antiviral strategy to combat SARS-CoV-2 and influenza. Cell.2020;181:865–876.e12. Available from: https://pubmed.ncbi.nlm.nih.gov/32353252/
- Nguyen TM, Zhang Y, Pandolfi PP. Virus against virus: a potential treatment for 2019-nCov (SARS-CoV-2) and other RNA viruses. Cell Res. Springer Nature. 2020;30:189–190. Available from: https://pubmed.ncbi.nlm.nih.gov/32071427/
- Pickar-Oliver A, Gersbach CA. The next generation of CRISPR–Cas technologies and applications. Nat Rev Mol Cell Biol. Nature Publishing Group. 2019;490–507. Available from: https://pubmed.ncbi.nlm.nih.gov/31147612/
- Anzalone AV, Koblan LW, Liu DR. Genome editing with CRISPR–Cas nucleases, base editors, transposases and prime editors. Nat Biotechnol. Nature Research. 2020;824–844. Available from: https://www.nature.com/articles/s41587-020-0561-9
- Kabadi A, McDonnell E, Frank CL, et al. Applications of functional genomics for drug discovery. SLAS Discov. SAGE Publications Inc. 2020. Available from: https://pubmed.ncbi.nlm.nih.gov/32026742/
- Bartha I, Di Iulio J, Venter JC, et al. Human gene essentiality. Nat Rev Genet. 2018;19:51–62. Available from: https://pubmed.ncbi.nlm.nih.gov/29082913/
- Fennell M, Xiang Q, Hwang A, et al. Impact of RNA-guided technologies for target identification and deconvolution. J Biomol Screen. SAGE Publications Inc. 2014;19:1327–1337. Available from: https://pubmed.ncbi.nlm.nih.gov/25163683/
- Yao Z, Petschnigg J, Ketteler R, et al. Application guide for omics approaches to cell signaling. Nat Chem Biol. Nature Publishing Group. 2015;11:387–397. Available from: https://pubmed.ncbi.nlm.nih.gov/25978996/
- Lin A, Giuliano CJ, Palladino A, et al. Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. Sci Transl Med. 2019;11:eaaw8412. Available from: https://pubmed.ncbi.nlm.nih.gov/31511426/
- Evers B, Jastrzebski K, Heijmans JPM, et al. CRISPR knockout screening outperforms shRNA and CRISPRi in identifying essential genes. Nat Biotechnol. 2016;34:631–633. Available from: https://pubmed.ncbi.nlm.nih.gov/27111720/
- Morgens DW, Deans RM, Li A, et al. Systematic comparison of CRISPR/Cas9 and RNAi screens for essential genes. Nat Biotechnol. 2016;34:634–636. Available from: https://pubmed.ncbi.nlm.nih.gov/27159373/
- Datlinger P, Rendeiro AF, Schmidl C, et al. Pooled CRISPR screening with single-cell transcriptome readout. Nat Methods. 2017;14:297–301. Available from: https://pubmed.ncbi.nlm.nih.gov/28099430/
- Schuster A, Erasimus H, Fritah S, et al. RNAi/CRISPR screens: from a pool to a valid hit. Trends Biotechnol. Elsevier Ltd. 2019;37:38–55. Available from: https://pubmed.ncbi.nlm.nih.gov/30177380/
- Doench JG. Am i ready for CRISPR? A user’s guide to genetic screens. Nat Rev Genet. Nature Publishing Group. 2018;19:67–80. Available from: https://pubmed.ncbi.nlm.nih.gov/29199283/
- Joung J, Konermann S, Gootenberg JS, et al. Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening. Nat Protoc. 2017;12:828–863. Available from: https://pubmed.ncbi.nlm.nih.gov/28333914/
- Shalem O, Sanjana NE, Hartenian E, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014;343:84–87. Available from: https://pubmed.ncbi.nlm.nih.gov/24336571/
- Wang T, Wei JJ, Sabatini DM, et al. Genetic screens in human cells using the CRISPR-Cas9 system. Science. 2014;343:80–84. Available from: https://pubmed.ncbi.nlm.nih.gov/24336569/
- Borys SM, Younger ST. Identification of functional regulatory elements in the human genome using pooled CRISPR screens. BMC Genomics. 2020;21. Available from https://pubmed.ncbi.nlm.nih.gov/32005150/
- Potting C, Crochemore C, Moretti F, et al. Genome-wide CRISPR screen for PARKIN regulators reveals transcriptional repression as a determinant of mitophagy. Proc Natl Acad Sci U S A. 2017;115:E180–E189. Available from: https://pubmed.ncbi.nlm.nih.gov/29269392/
- Li Y, Muffat J, Javed AO, et al. Genome-wide CRISPR screen for Zika virus resistance in human neural cells. Proc Natl Acad Sci U S A. 2019;116:9527–9532. Available from: https://pubmed.ncbi.nlm.nih.gov/31019072/
- Kramer NJ, Haney MS, Morgens DW, et al. CRISPR-Cas9 screens in human cells and primary neurons identify modifiers of C9ORF72 dipeptide-repeat-protein toxicity. Nat Genet. [Internet]. 2018 [cited 2020 Jul 16];50:603–612. Available from: https://pubmed.ncbi.nlm.nih.gov/29507424/
- Kim HS, Lee K, Kim SJ, et al. Arrayed CRISPR screen with image-based assay reliably uncovers host genes required for coxsackievirus infection. Genome Res.2018;28:859–868. Available from: http://www.genome.org/cgi/doi/10.1101/gr.230250.117
- Dede M, Kim E, Hart T. Biases and blind-spots in genome-wide CRISPR knockout screens. bioRxiv. 2020 Available from: https://www.biorxiv.org/content/10.1101/2020.01.16.909606v1
- Pettitt SJ, Krastev DB, Brandsma I, et al. Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance. Nat Commun. 2018;9. Available from: https://pubmed.ncbi.nlm.nih.gov/29748565/
- Hultquist JF, Schumann K, Woo JM, et al. A Cas9 ribonucleoprotein platform for functional genetic studies of HIV-host interactions in primary human T cells. Cell Rep. 2016;17:1438–1452. Available from: https://pubmed.ncbi.nlm.nih.gov/27783955/
- Tan J, Martin SE. Validation of synthetic CRISPR reagents as a tool for arrayed functional genomic screening. PLoS One. 2016;11:e0168968. Available from: https://pubmed.ncbi.nlm.nih.gov/28030641/
- Strezoska Ž, Perkett MR, Chou ET, et al. High-content analysis screening for cell cycle regulators using arrayed synthetic crRNA libraries. J Biotechnol. 2017;251:189–200. Available from: https://pubmed.ncbi.nlm.nih.gov/28445693/
- Turner RJ, Golz S, Wollnik C, et al. A whole genome-wide arrayed CRISPR screen in primary organ fibroblasts to identify regulators of kidney fibrosis. SLAS Discov. 2020;25:591–604. Available from: https://pubmed.ncbi.nlm.nih.gov/32425084/
- Cui Y, Xu J, Cheng M, et al. Review of CRISPR/Cas9 sgRNA design tools. Interdiscip Sci Comput Life Sci. Springer Berlin Heidelberg. 2018;10:455–465. Available from: https://pubmed.ncbi.nlm.nih.gov/29644494/
- Clement K, Hsu JY, Canver MC, et al. Technologies and computational analysis strategies for CRISPR applications. Mol Cell. Cell Press. 2020;79:11–29. Available from: https://pubmed.ncbi.nlm.nih.gov/32619467/
- Smith I, Greenside PG, Natoli T, et al. Evaluation of RNAi and CRISPR technologies by large-scale gene expression profiling in the connectivity map. PLoS Biol. 2017;15:e2003213. Available from: https://pubmed.ncbi.nlm.nih.gov/29190685/
- Lin A, Sheltzer JM. Discovering and validating cancer genetic dependencies: approaches and pitfalls. Nat Rev Genet. Nature Research. 2020;21:671–682. Available from: https://pubmed.ncbi.nlm.nih.gov/32561862/
- Morita E, Arii J, Christensen D, et al. Attenuated protein expression vectors for use in siRNA rescue experiments. Biotechniques. 2012. Available from: https://pubmed.ncbi.nlm.nih.gov/22877307/
- Lin A, Giuliano CJ, Sayles NM, et al. CRISPR/Cas9 mutagenesis invalidates a putative cancer dependency targeted in on-going clinical trials. Elife. 2017;6. Available from: https://pubmed.ncbi.nlm.nih.gov/28337968/
- Neggers JE, Kwanten B, Dierckx T, et al. Target identification of small molecules using large-scale CRISPR-Cas mutagenesis scanning of essential genes. Nat Commun. 2018;9. Available from: https://pubmed.ncbi.nlm.nih.gov/29402884/
- Merkert S, Martin U. Site-specific genome engineering in human pluripotent stem cells. Int J Mol Sci. MDPI AG. 2016;17:1000. Available from: https://pubmed.ncbi.nlm.nih.gov/27347935/
- Garg P, Oikonomopoulos A, Chen H, et al. Genome editing of induced pluripotent stem cells to decipher cardiac channelopathy variant. J Am Coll Cardiol. 2018;72:62–75. Available from: https://pubmed.ncbi.nlm.nih.gov/29957233/
- Ahmad G, Amiji M. Use of CRISPR/Cas9 gene-editing tools for developing models in drug discovery Drug Discov Today. Elsevier Ltd. 2018;23:519–533. Available from: https://pubmed.ncbi.nlm.nih.gov/29326075/
- Zarei A, Razban V, Hosseini SE, et al. Creating cell and animal models of human disease by genome editing using CRISPR/Cas9. J Gene Med. Blackwell Publishing Inc. 2019;21:e3082. Available from: https://pubmed.ncbi.nlm.nih.gov/30786106/
- Musunuru K, Genome editing of human pluripotent stem cells to generate human cellular disease models. DMM Dis Model Mech. 2013;6:896–904. Available from: https://pubmed.ncbi.nlm.nih.gov/23751357/
- Kim J, Lana B, Torelli S, et al. A new patient‐derived iPSC model for dystroglycanopathies validates a compound that increases glycosylation of α‐dystroglycan. EMBO Rep.2019;20. Available from: https://pubmed.ncbi.nlm.nih.gov/31566294/
- De Masi C, Spitalieri P, Murdocca M, et al. Application of CRISPR/Cas9 to human-induced pluripotent stem cells: from gene editing to drug discovery. Hum Genomics. 2020;14. Available from: https://pubmed.ncbi.nlm.nih.gov/32591003/
- Garcia-Leon JA, Vitorica J, Gutierrez A. Use of human pluripotent stem cell-derived cells for neurodegenerative disease modeling and drug screening platform. Future Med Chem. Future Medicine Ltd. 2019;11:1305–1322. Available from: https://pubmed.ncbi.nlm.nih.gov/31161803/
- Mohamed NV, Larroquette F, Beitel LK, et al. One step into the future: new iPSC tools to advance research in Parkinson’s disease and neurological disorders. J Parkinsons Dis. IOS Press. 2019;9:265–281. Available from: https://pubmed.ncbi.nlm.nih.gov/30741685/
- Yun Y, Ha Y. CRISPR/Cas9-mediated gene correction to understand ALS. Int J Mol Sci. 2020;21:3801. Available from: https://pubmed.ncbi.nlm.nih.gov/32471232/
- Edmondson R, Broglie JJ, Adcock AF, et al. Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors. Assay Drug Dev Technol. Mary Ann Liebert Inc. 2014;12:207–218. Available from: https://pubmed.ncbi.nlm.nih.gov/24831787/
- Yu F, Hunziker W, Choudhury D. Engineering microfluidic organoid-on-a-chip platforms. Micromachines. 2019;10:165. Available from: https://pubmed.ncbi.nlm.nih.gov/30818801/
- Salick MR, Lubeck E, Riesselman A, et al. The future of cerebral organoids in drug discovery. Semin Cell Dev Biol. Elsevier Ltd. 2020. Available from: https://pubmed.ncbi.nlm.nih.gov/32654970/
- Takeda H, Kataoka S, Nakayama M, et al. CRISPR-Cas9-mediated gene knockout in intestinal tumor organoids provides functional validation for colorectal cancer driver genes. Proc Natl Acad Sci U S A. 2019;116:15635–15644. Available from: https://pubmed.ncbi.nlm.nih.gov/31300537/
- Alić I, Goh PA, Murray A, et al. Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain. Mol Psychiatry. 2020. Available from: http://www.nature.com/articles/s41380-020-0806-5
- Capecchi MR, Gene targeting in mice: functional analysis of the mammalian genome for the twenty-first century. Nat Rev Genet. 2005;6:507–512. Available from: https://pubmed.ncbi.nlm.nih.gov/15931173/
- Qin W, Wang H. Delivery of CRISPR-Cas9 into mouse zygotes by electroporation. Methods Mol Biol. Humana Press Inc.. 2019;1874:179–190.
- Klimke A, Güttler S, Kuballa P, et al. Use of CRISPR/Cas9 for the modification of the mouse genome. Methods Mol Biol. . Humana Press Inc. 2019:213–230. Available from: https://pubmed.ncbi.nlm.nih.gov/30912024/
- Wang H, Yang H, Shivalila CS, et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/cas-mediated genome engineering. Cell. 2013;153:910–918. Available from: https://pubmed.ncbi.nlm.nih.gov/23643243/
- Sato M, Takabayashi S, Akasaka E, et al. Recent advances and future perspectives of in vivo targeted delivery of genome-editing reagents to germ cells, embryos, and fetuses in mice. Cells. 2020;9:799. Available from: https://pubmed.ncbi.nlm.nih.gov/32225003/
- Lee H, Yoon DE, Kim K. Genome editing methods in animal models [Internet]. Animal Cells Syst (Seoul). Taylor and Francis Ltd. 2020;24:8–16. Available from: https://pubmed.ncbi.nlm.nih.gov/32158611/
- Irion U, Krauss J, Nüsslein-Volhard C. Precise and efficient genome editing in zebrafish using the CRISPR/Cas9 system. Dev. 2014;141:4827–4830. Available from: https://pubmed.ncbi.nlm.nih.gov/25411213/
- Yan S, Tu Z, Liu Z, et al. A Huntingtin Knockin pig model recapitulates features of selective neurodegeneration in Huntington’s disease. Cell. 2018;173:989–1002.e13. Available from: https://pubmed.ncbi.nlm.nih.gov/29606351/
- Yamanaka S, Takahashi K, Okita K, et al. Induction of pluripotent stem cells from fibroblast cultures. Nat Protoc. 2007;2:3081–3089. Available from: https://pubmed.ncbi.nlm.nih.gov/18079707/
- Cong L, Ran FA, Cox D, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339:819–823. Available from: https://pubmed.ncbi.nlm.nih.gov/23287718/
- Mali P, Yang L, Esvelt KM, et al. RNA-guided human genome engineering via Cas9. Science. 2013;339:823–826. Available from: https://pubmed.ncbi.nlm.nih.gov/23287722/
- Ou Z, Niu X, He W, et al. The combination of CRISPR/Cas9 and iPSC technologies in the gene therapy of human β-thalassemia in mice. Sci Rep. 2016;6. Available from: https://pubmed.ncbi.nlm.nih.gov/27581487/
- Wu Y, Zeng J, Roscoe BP, et al. Highly efficient therapeutic gene editing of human hematopoietic stem cells. Nat Med. 2019;25:776–783. Available from: https://pubmed.ncbi.nlm.nih.gov/30911135/
- Li C, Mei H, Hu Y. Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy. Brief Funct Genomics. 2020;19:175–182.
- Gao Q, Dong X, Xu Q, et al. Therapeutic potential of CRISPR/Cas9 gene editing in engineered T-cell therapy. Cancer Med. Blackwell Publishing Ltd. 2019;8:4254–4264. Available from: https://pubmed.ncbi.nlm.nih.gov/31199589/.
- Roth TL, Puig-Saus C, Yu R, et al. Reprogramming human T cell function and specificity with non-viral genome targeting. Nature. [Internet]. 2018 [cited 2020 Jul 16];559:405–409. Available from: https://pubmed.ncbi.nlm.nih.gov/29995861/
- Albers JJ, Ammon T, Gosmann D, et al. Gene editing enables T-cell engineering to redirect antigen specificity for potent tumor rejection. Life Sci Alliance. 2019;2:e201900367. Available from: /pmc/articles/PMC6421629/?report=abstract
- Rath JA, Arber C. Engineering strategies to enhance TCR-based adoptive T cell therapy. Cells. NLM (Medline). 2020;9:1485. Available from: https://pubmed.ncbi.nlm.nih.gov/32570906/
- Xiao Q, Guo D, Chen S. Application of CRISPR/Cas9-based gene editing in HIV-1/AIDS therapy. Front Cell Infect Microbiol. Frontiers Media S.A. 2019. Available from: https://pubmed.ncbi.nlm.nih.gov/30968001/
- Min Y-L, Bassel-Duby R, Olson EN. CRISPR correction of duchenne muscular dystrophy. Annu Rev Med. 2019;70:239–255. Available from: https://pubmed.ncbi.nlm.nih.gov/30379597/
- Ekman FK, Ojala DS, Adil MM, et al. CRISPR-Cas9-mediated genome editing increases lifespan and improves motor deficits in a Huntington’s disease mouse model. Mol Ther Nucleic Acids. 2019;17:829–839. Available from: https://pubmed.ncbi.nlm.nih.gov/31465962/
- Yang S, Chang R, Yang H, et al. CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington’s disease. J Clin Invest. 2017;127:2719–2724. Available from: https://pubmed.ncbi.nlm.nih.gov/28628038/
- Park H, Oh J, Shim G, et al. In vivo neuronal gene editing via CRISPR–Cas9 amphiphilic nanocomplexes alleviates deficits in mouse models of Alzheimer’s disease. Nat Neurosci. 2019;22:524–528. Available from: https://pubmed.ncbi.nlm.nih.gov/30858603/
- Lim CKW, Gapinske M, Brooks AK, et al. Treatment of a mouse model of ALS by in vivo base editing. Mol Ther. 2020;28:1177–1189. Available from: https://pubmed.ncbi.nlm.nih.gov/31991108/
- Zheng N, Li L, Wang X. Molecular mechanisms, off-target activities, and clinical potentials of genome editing systems. Clin Transl Med.2020;10:412–426. Available from: https://pubmed.ncbi.nlm.nih.gov/32508055/
- Lee J, Bayarsaikhan D, Bayarsaikhan G, et al. Recent advances in genome editing of stem cells for drug discovery and therapeutic application. Pharmacol Ther. Elsevier Inc. 2020;209:107501. Available from: https://pubmed.ncbi.nlm.nih.gov/32061705/
- Haapaniemi E, Botla S, Persson J, et al. CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response. Nat Med. 2018;24:927–930. Available from: https://pubmed.ncbi.nlm.nih.gov/29892067/
- Ihry RJ, Worringer KA, Salick MR, et al. P53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells. Nat Med. 2018;24:939–946. Available from: https://pubmed.ncbi.nlm.nih.gov/29892062/
- Wang D, Zhang F, Gao G. CRISPR-based therapeutic genome editing: strategies and in vivo delivery by AAV vectors. Cell. Cell Press. 2020;181:136–150. Available from: https://pubmed.ncbi.nlm.nih.gov/32243786/
- Aghamiri S, Talaei S, Ghavidel AA, et al. Nanoparticles-mediated CRISPR/Cas9 delivery: recent advances in cancer treatment. J Drug Deliv Sci Technol. Editions de Sante. 2020;56:101533.
- Wei T, Cheng Q, Min YL, et al. Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing. Nat Commun. 2020;11. Available from: https://pubmed.ncbi.nlm.nih.gov/32591530/